Four drug metabolism-related subgroups of pancreatic adenocarcinoma in prognosis, immune infiltration, and gene mutation

Abstract: We aimed to screen the drug metabolism-related subgroups of pancreatic adenocarcinoma (PAAD) and to study the prognosis, clinical features, immune infiltration, and gene mutation differences of different subtypes in PAAD patients. All 181 cases of PAAD samples and clinical characteristics data were downloaded from The Cancer Genome Atlas (TCGA). After matching the drug metabolism-related genes downloaded from PMID 33202946 with the TCGA dataset, the drug metabolism-related genes were initially obtained. Besides, univariate Cox regression analysis was used to screen the drug metabolism genes related to the prognosis of PAAD. Moreover, the construction of the protein–protein interaction (PPI) network and gene ontology were performed. The four subgroups of PAAD obtained from unsupervised clustering analysis were systematically analyzed, including prognostic, GSVA, immune infiltration, and gene mutation analysis. A total of 83 drug metabolism genes related to the prognosis of PAAD were obtained and enriched in 16 pathways. The PPI network was composed of 248 relationship pairs. Four subgroups that can identify different subtypes of PPAD were obtained, and there were significant differences in survival and clinical characteristics, mutation types, and immune infiltration abundance between subgroups. A total of 17 different pathways among the four subgroups involved in cell cycle, response to stimulants such as drugs, and transmembrane transport. In this study, the four subgroups related to the drug metabolism of PAAD were comprehensively analyzed, and the important role of drug metabolism-related genes in the immune infiltration and prognosis of PAAD were emphasized.

Keywords: pancreatic adenocarcinoma, drug metabolism genes, prognosis, immune infiltration, unsupervised clustering analysis

1 Introduction

The death of pancreatic ductal adenocarcinoma, also known as pancreatic adenocarcinoma (PAAD), is one of the highly lethal cancer types [1–3]. Because PAAD is very difficult to prevent or diagnose early in the curable stage and the prognosis is not ideal, the diagnosis and staging of PAAD is the key to the treatment of this disease [4]. For the treatment of patients with PAAD, conventional combined chemotherapy has made significant progress in the treatment of PAAD. However, the subtypes of the disease present broad resistance to therapy [5]. Therefore, comprehensive and accurate diagnosis and treatment strategies such as personalized and targeted therapy based on tumor and genomic markers have great application prospects [6].

The in-depth understanding and research of PAAD-related gene regulation can provide a theoretical basis for the molecular targeted therapy of PAAD. KRAS proto-oncogene, GTPase (KRAS), and tumor protein p53 (TP53) were confirmed to be important biomarkers for the prognosis of PAAD, and can also be used as a tool for treatment prediction [7]. It was well known that TP53 was a tumor suppressor, and mutations of TP53 can be detected in 70% of PAAD patients [8]. The mutation of TP53 in PAAD patients mainly led to the loss of DNA binding ability, which in turn resulted in the loss of gene transcription activation [9]. For example, compared with patients whose TP53 function was completely lost due to mutations, patients with normal TP53 expression had significantly improved survival [10]. Therefore, it is suggested that TP53 can be used as a biomarker for the prognosis of PAAD and treatment.
prediction. As for KRAS, it is a small GTPase (21 kDa) and 95% of PAAD patients had KRAS mutations [11], which caused KRAS to be constitutively activated resulting in uncontrolled cell proliferation and other processes that led to the development and spread of cancer [12]. The results of multiple studies have shown that compared with patients with wild-type KRAS, patients with KRAS mutations showed worse responses to gemcitabine or erlotinib and worse survival [13,14]. These molecular markers may play an important role in the future treatment of PAAD. However, the research and application of PAAD drug metabolism genes in the field of therapy and prognosis are still very limited.

Compared with molecular targeted therapy, immunotherapy has little effect on PAAD, not only because of its immunosuppressive tumor microenvironment but also because of the unclear role of immune cells in PAAD [15]. The screening of immune cells related to the clinical characteristics of PAAD may have guiding significance for the early diagnosis of PAAD patients. Studies have shown that the expression of CD8+ T cells was correlated with the survival time of PAAD [16]. In particular, high tumor infiltration of CD8+ T cells can lead to a better prognosis. In addition, the synergistic activation of T and natural killer (NK) cells in a transgenic mouse model of resectable PDAC has been shown to prevent the recurrence of PAAD [17]. Therefore, detecting the expression of immune cells may be important for judging the prognosis of patients with PAAD.

Currently, there is no joint study of drug metabolism-related genes with the immune infiltration and prognosis of PAAD. In this research, PAAD tumor data were downloaded from The Cancer Genome Atlas (TCGA), and multiple data mining methods were used to further screen drug metabolism-related genes and analyze PAAD subgroups that were related to the prognosis of PAAD (Figure A1). This research may contribute to exploring the relevance between the drug metabolism-related genes and the prognosis of PAAD as well as immune infiltration of PAAD.

2 Materials and methods

2.1 Data acquisition and screening

A total of 181 PAAD case samples and clinical data were downloaded from the TCGA dataset (http://xena.ucsc.edu) [18], and 177 PAAD samples included in this study (all tumors samples) were obtained after excluding the adjacent samples (TCGA.H6.A45N.11A, TCGA.H6.8124.11A, TCGA.YB.A89D.11A, TCGA.HV.A5A3.11A). For the data quality control (QC), the count value of the PAAD gene expression matrix was used for log2(count + 1) standardization, and then 60,489 transcripts were merged with the same transcripts through Python (the mean method for processing). After removing the genes whose expression level was 0, 31,186 Ensembl_IDs were obtained. Gencode (ftp://ftp.sanger.ac.uk/pub/gencode/Gencode_human/) was used for gene annotation of the transcriptome. In addition, the conversion between Ensembl_IDs and Symbol ID was performed on Python. The “normalizeBetweenArrays” function in the R language limma 3.9.19 package was used to normalize the data [19]. Finally, 298 drug metabolism-related genes were downloaded from PMID 33202946. Besides, through matching with the TCGA data set (PAAD) and eliminating genes with missing values less than 50%, the drug metabolism-related gene expression matrix was set for subsequent clustering studies.

3 Screening of prognostic related genes

In order to screen the drug metabolism genes related to the prognosis of PAAD, the R language Survival Package (version3.10.3, http://www.bioconductor.org/packages/release/bioc/html/survival.html) was used for univariate Cox regression analysis based on the sample survival information of the TCGA data set and the gene expression value in each sample [20].

3.1 Construction of protein–protein-interaction (PPI) network and pathway enrichment analysis

In order to explore the interaction of the expressed proteins of drug metabolism-related genes, PPI prediction analysis was performed on the prognostic-related drug metabolism proteins obtained above. STRING (v9.1) (https://www.string-db.org) was applied in the construction of the PPI network, and a threshold (score threshold = 0.4) was set to draw the online protein interaction network. In addition, the PPI score (score threshold = 0.4) was adopted to show the PPI interaction relationship more clearly. The Cytoscape (v3.8.2) tool software (https://github.com/cytoscape/cytoscape.js/tree/v3.8) was used to draw the network diagram.
The R language ClusterProfiler (v3.16.1) package (http://bioconductor.org/packages/release/bioc/html/clusterProfiler.html) was used for pathway enrichment analysis [21]. Moreover, through gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases, pathway enrichment analysis was performed on prognostic-related drug metabolism genes, and the false discovery rate (FDR) method was used to correct the P value. Finally, the ClusterProfiler (v3.16.1) package was used to draw the pathway enrichment map.

### 3.2 Unsupervised clustering analysis

To further determine the regulation mechanism of different drug metabolism-related genes in patients with PAAD, unsupervised clustering analysis was performed by the R language NbClust package (v 3.0), which was used in all TCGA samples (177 cases) (https://cran.r-project.org/web/packages/NbClust/index.html) to determine the best classification group [22]. Then, clustering was performed on the k-mean method provided by the NbClust package. Finally, principal components analysis (PCA, R language dplyr package v 1.0.5, https://cran.r-project.org/web/packages/dplyr/, prcomp function) and linkage clustering analysis (R language pheatmap package v 1.0 .12, https://cran.r-project.org/web/packages/pheatmap/) were used to explore the differences between different subgroups.

### 3.3 Gene set variation analysis (GSVA) of different subgroups

In order to explore the differences in the pathway scoring status of the four different subgroups, we used GO (http://software.broadinstitute.org/gsea/msigdb) as a reference set and conducted the subgroup of 177 samples through the ‘gsva’ method provided by the R language GSVA (v 3.10.3, http://www.bioconductor.org/packages/release/bioc/html/GSVA.html). First, linkage cluster analysis was used to explore whether different subgroups have associated clustering patterns on GSVA scores and whether there was a linkage between subgroups. If linkage existed, subgroups were considered to be combined and participated in the analysis of the pathway score. Limma package (v 3.44.3) of R was used to analyze the different pathways among subgroups.

### 3.4 Prognostic survival analysis and clinical information association analysis among subgroups

The R language Survival (v3.2-10) package (Version3.10.3, http://www.bioconductor.org/packages/release/bioc/html/survival.html) was used for prognostic risk difference analysis based on the survival matrix of the subgroups and subtype groupings. In addition, the Kaplan–Meier (K–M) survival prognostic curve (P value < 0.05) was used to explore the difference between different subgroups.

Then, TCGA clinical data were used to count the number of WHO grades (G), sex ratios, age distributions, and responses to chemotherapy (complete response, CR; partial response, PR; progressive response, PD; stable disease, SD) included in each subtype. In addition, the Chi-square test in the MASS (v 7.3-53.1) package of R language was used to calculate whether there were differences in different clinical characteristics of each subgroup. Because each subgroup contained different number of people, the above clinical characteristics were counted as “percentage = count/total number of people” as the final index included in the study. Finally, ggplot2 was applied in the drawing of bar graphs.

### 3.5 Analysis of the abundance of immune infiltration in subgroups

In order to explore the differences in the abundance of immune infiltration between subgroups, 177 TCGA samples were included in this part of the study. Immune infiltration analysis was performed by the CIBERSORT (R 4.0.2) package [23], which used a leukocyte signature matrix (LM22). Besides, a variety of immune cell types in all PAAD samples were analyzed by the deconvolution method [24]. After calculating the proportion of immune infiltrating cells, the Mann–Whitney U-test was used to compare and analyze the differences in the proportion of immune infiltration of patients in different subgroups.

Furthermore, we searched for markers of different M2 macrophages subtypes (M2a, M2b, M2c, M2d) from the published literature [25,26]. The number of markers for M2a, M2b, M2c, and M2d are 6 (CD163, CD200R1, CD206, TGM2, IL1R2, CD209), 2 (CD163, CD86), 3 (CD163, TLR1, TLR8), and 2 (VEGF, IL10), respectively. Next, based on the expression matrix of all genes, the ssGSEA (single sample enrichment analysis) algorithm was used to
estimate the relative infiltration level of each M2 macrophages subtype. Then, the t-test was used to compare whether there was a significant difference between the M2 macrophages subtypes of each two clusters. \( P < 0.05 \) was considered as a statistically significant threshold.

3.6 Analysis of gene mutations in subgroups

In order to explore the differences in gene mutations between different subgroups, PAAD genome Maf files (somatic mutations) and corresponding clinical signature files in the TCGA database were adopted. At first, the genomic Maf files of different subgroups were separated. Then, the maftools package of R language was used to perform gene mutation analysis [27], and the mutation waterfall chart of different subtypes was drawn. Finally, the mutation information of different subgroups was counted. Furthermore, we selected the top 2 genes with mutation frequency in each subgroup and analyzed the KEGG pathways of these genes that were significantly different between mutant and nonmutant samples.

4 Results

4.1 Eighty-three drug metabolism genes were related to the prognosis of PAAD

A total of 177 cases of TCGA expression matrix were included in this study (Table S1). The TCGA expression matrix included 31,186 genes and the clinical phenotypes, namely, WHO grade, gender, age, response to chemotherapy (SD, PD, CR, and PR), TNM classification (TNM), and tumor stage ([Table S2]).

After the intersection of the 298 reported drug metabolism genes with TCGA (Table S3), a total of 270 genes were used as the drug metabolism-related gene expression matrix for subsequent clustering studies (Table S4). The results of univariate Cox regression analysis between the survival data of 177 samples in TCGA and 270 drug metabolism genes suggested that 83 genes had a significant correlation with the prognosis of PAAD \( (P < 0.05) \) (Table S5).

4.2 PPI network construction and pathway enrichment analysis results

The PPI network of 83 PAAD prognosis-related drug metabolism proteins was constructed using Cytoscape (Figure 1a). A total of 248 interactions relationship pairs were obtained with an interaction score >0.4 (Table S6). It can be seen that in the PPI network the two relationship pairs with the highest degree of connection were ABCC8 (ATP binding cassette subfamily Cc member 8) – KCNJ11 (potassium inwardly rectifying channel subfamily j member 11) and PPARG (peroxisome proliferator activated receptor gamma) – RXRA (retinoid \( \times \) receptor alpha).

Besides, the enrichment analysis of KEGG and GO pathways was performed on the 83 genes, and a total of eight KEGG and eight GO pathways were enriched. The eight enriched KEGG pathways were as follows: drug metabolism-cytochrome P450, metabolism of xenobiotic by cytochrome P450, chemical carcinogenesis, retinol metabolism, drug metabolism-other enzymes, bile secretion, ABC transporters, and tyrosine metabolism (Figure 1b). Moreover, the GO pathway included xenobiotic metabolic process, response to xenobiotic stimulus, cellular response to xenobiotic stimulus, hormone metabolism, cellular hormone metabolic process, steroid metabolic process, retinoic acid metabolic process, and drug catabolic process (Figure 1c).

4.3 PAAD subgroups were obtained from unsupervised clustering analysis

Based on the 83 drug metabolism-related genes, patients were divided into different subgroups through unsupervised cluster analysis. As shown in Figure 2a, as the number of clusters increased, the total within sum of square (WSS) gets smaller. When the WSS decreased slowly, the effect of further increasing the number of clusters was considered not to be better, and this point was the optimal number of clusters. The final result showed that the samples can be divided into four subgroups (Figure 2a). Moreover, Cluster 1, Cluster 2, Cluster 3, and Cluster 4 contained 48, 55, 8 and 66 people, respectively (Table S7), and the linkage clustering heat map revealed that although there was a certain correlation between samples in different groups, the correlation between the same subgroup was greater, and the correlation was also reflected in different clinical characteristics (Figure 2b). Furthermore, it can be seen from PCA that the four groups were separated well (Figure 2c, Dim1 = 28.1%).

4.4 Prognostic K–M survival analysis and clinical information association analysis results

For the above four subgroups (Clusters 1–4), the survival data of TCGA were used for K–M survival analysis. The
Figure 1: Protein–protein interaction network (PPI) and enrichment analysis of 83 drug metabolism genes: (a) PPI network; (b) enrichment results of Kyoto encyclopedia of genes and genomes (KEGG); and (c) enrichment results of gene ontology (GO).

Figure 2: Unsupervised clustering of 83 drug metabolism genes: (a) the best type was determined; (b) linkage association clustering analysis (Clusters1–4); and (c) principal components analysis (PCA) of subgroup clustering.
results suggested that there were significant differences among the four subgroups (Figure 3a, \( P = 0.0017 \)), confirming that the obtained subgroups were real. In addition, the results of clinical information association analysis showed significant differences in the four subgroups (Figure 3b–f). These differences were reflected in the WHO classification (G1, G2, and G3), gender ratio, survival status, and response to chemotherapy (CR, PR, PD, and SD) (Table 1, \( p < 0.001 \)). In the Cluster 1 subgroup, there were more individuals with the age of <65 years, WHO G2 grade, and PR, but the survival rate was relatively lower. Similar to Cluster 1, in Cluster 2, the WHO classification results showed that G2 > G3 > G1 and the survival rate was relatively low. The difference was that more individuals in this subgroup were >65 years old and PD. Moreover, the age of all patients in the clusters was less than 65. All patients in Cluster 3 alive were alive with CR. After WHO classification, the G1 level had a clear advantage. In Cluster 4, the proportion of SD was slightly higher than that in other subgroups.

### 4.5 GSVA analysis of different subgroups

The correlation between the significantly enriched GO pathways was explored through linkage association cluster analysis (Figure 4a). From the perspective of subgroups, we can clearly see that the four subgroups formed interlocking modules, indicating significant differences in GO pathways between the four groups (Figure 4b). In addition, multi-group square difference analysis was used to explore significantly different GO pathways among the four subgroups, and the results indicated 17 significantly different pathways including cell cycle, metabolism and synthesis of organic matter, response to stimulants such as drugs, and transmembrane transport (Figure 4c).

### 4.6 Abundance analysis for immune infiltration among subgroups

The CIBERSORT algorithm was used to calculate the 22 immune infiltration abundances among the above subgroups, and more than 50% of immune cells with no immune abundance were excluded. Finally, 12 immune cells were included in the study (Table S8). Furthermore, the 12 immune cells were subjected to the Whitney U-test (Table S9). The results indicated that the immune score of immune cells varies among different subgroups (Figure 5a). Compared with the other three clusters, M2 macrophages had the highest immune score in Cluster 3, while M0 macrophages and M1 macrophages had the lowest immune score.
Table 1: Comparison of clinical characteristics distribution differences among different subgroups of TCGA

| Phenotype                  | Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | P value |
|---------------------------|-----------|-----------|-----------|-----------|---------|
| Age <65                   | 56.25     | 30.91     | 75.00     | 46.97     | 0.00*** |
| Age ≥65                   | 43.75     | 69.09     | 25.00     | 53.03     |         |
| State Alive               | 39.58     | 38.18     | 100.00    | 56.06     | 0.00*** |
| Gender Male               | 47.92     | 61.82     | 50.00     | 51.52     |         |
| Gender Female             | 52.08     | 30.91     | 50.00     | 48.48     | 0.07    |
| Tumor stage Early         | 95.83     | 92.73     | 87.50     | 93.94     | 0.34    |
| Tumor stage Advance       | 4.17      | 7.27      | 12.5      | 6.06      |         |
| WHO G1                    | 6.25      | 10.91     | 87.50     | 21.21     | 0.00*** |
| WHO G2                    | 56.25     | 61.82     | 12.5      | 50.00     |         |
| WHO G3                    | 37.50     | 23.64     | 0.00      | 25.76     |         |
| WHO G4                    | 0.00      | 3.64      | 0.00      | 3.03      |         |
| Chemotherapy response CR  | 2.08      | 10.91     | 50.00     | 19.70     | 0.00*** |
| Chemotherapy response PR  | 27.08     | 3.64      | 0.00      | 3.03      |         |
| Chemotherapy response PD  | 4.17      | 34.55     | 0.00      | 21.21     |         |
| Chemotherapy response SD  | 0.00      | 3.64      | 0.00      | 6.06      |         |

***P value <0.001.

Figure 4: Gene set variation analysis: (a) the linkage-heatmap describes the existence of linkage correlation modules between the GSVA scores of the GO pathway; (b) the linkage-heatmap describes the correlation modules that are linked between the GSVA scores within different subtypes of TCGA; (c) significant differences in GO pathways (P value <0.05) in the heatmap can see obvious stratification in the four subgroups.
in Cluster 3 (Figure 5a). Further analysis of different subtypes of M2 macrophages (M2a, M2b, M2c, M2d) showed that the infiltration levels of the four subtypes were basically consistent among different subgroups (Figure 5b). In the same subgroup, M2b macrophages had the highest infiltration level, followed by M2a macrophages, then M2c macrophages, and finally, M2d macrophages.

4.7 Gene mutation analysis for subgroups

Four sets of different mutation waterfall charts were drawn to count the mutation information of different subgroups (Figure 6, Table 2). The results showed that there were differences in the mutant genes and the mutation frequency among the 4 subgroups (Table 3). Besides,
KRAS and TP53 with the highest mutation frequency in Clusters 1, 2, and 4 did not appear in the Top 10 mutation frequencies of the Cluster 3 subgroup.

To further analyze whether the genes with missense mutation might have functional changes and further affect the pathway, we selected the genes with high missense mutation frequency (KRAS, TP53, RGPD3) in different subgroups for further analysis. The pathways with differences between mutant and nonmutant KRAS samples in Cluster 1 included taurine and hypotaurine metabolism, regulation of autophagy, pancreatic cancer, etc. (Figure 7a). KRAS mutations in Cluster 2 involved changes in pathways such as taurine and hypotaurine metabolism, immunodeficiency, antigen processing and presentation (Figure 7b). For Cluster 4, there were 27 patients with mutations in the KRAS (Figure 6). There were differences in multiple pathways between patients in the KRAS gene mutation group and patients in the nonmutation group, including immunodeficiency, natural killer cell-mediated cytotoxicity, JAK stat signaling pathway, etc. (Figure 7c). TP53

Table 2: Statistics of the number of mutant genes in different subgroups

| Type               | Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 |
|--------------------|-----------|-----------|-----------|-----------|
| Missense mutation  | 224       | 302       | 12        | 77        |
| Nonsense mutation  | 9         | 11        | 1         | 9         |
| Total              | 234       | 313       | 13        | 86        |

KRAS and TP53 with the highest mutation frequency in Clusters 1, 2, and 4 did not appear in the Top 10 mutation frequencies of the Cluster 3 subgroup.

To further analyze whether the genes with missense mutation might have functional changes and further affect the pathway, we selected the genes with high missense mutation frequency (KRAS, TP53, RGPD3) in different subgroups for further analysis. The pathways with differences between mutant and nonmutant KRAS samples in Cluster 1 included taurine and hypotaurine metabolism, regulation of autophagy, pancreatic cancer, etc. (Figure 7a). KRAS mutations in Cluster 2 involved changes in pathways such as taurine and hypotaurine metabolism, immunodeficiency, antigen processing and presentation (Figure 7b). For Cluster 4, there were 27 patients with mutations in the KRAS (Figure 6). There were differences in multiple pathways between patients in the KRAS gene mutation group and patients in the nonmutation group, including immunodeficiency, natural killer cell-mediated cytotoxicity, JAK stat signaling pathway, etc. (Figure 7c). TP53

Table 3: Top 10 mutated genes in different subgroups

|                | Cluster 1 | Frq | Cluster 2 | Frq | Cluster 3 | Frq | Cluster 4 | Frq |
|----------------|-----------|-----|-----------|-----|-----------|-----|-----------|-----|
| Top1           | KRAS      | 0.19| KRAS      | 0.53| CYP2C8    | 0.13| TP53      | 0.08|
| Top2           | TP53      | 0.08| TP53      | 0.11| ESRRB     | 0.13| KRAS      | 0.06|
| Top3           | FLG       | 0.06| GNAS      | 0.07| FN1       | 0.13| CDKN2A    | 0.03|
| Top4           | C2orf16   | 0.06| ADAMTS15  | 0.04| GANAB     | 0.13| AGXT      | 0.02|
| Top5           | APOB      | 0.04| ADAMTS13  | 0.04| MACF1     | 0.13| AHNK      | 0.02|
| Top6           | FCR5      | 0.04| NOS3      | 0.04| NSUN7     | 0.13| AKAP6     | 0.02|
| Top7           | KCHN7     | 0.04| PSD       | 0.04| PROM15    | 0.13| AOC1      | 0.02|
| Top8           | NEB       | 0.04| TENM2     | 0.04| SNAP47    | 0.13| APBA2     | 0.02|
| Top9           | PLEKHH2   | 0.04| TGFR2     | 0.04| SRSF6     | 0.13| AQP4      | 0.02|
| Top10          | SPTA1     | 0.04| TMEM108   | 0.04| TRIM47    | 0.13| ATP9A     | 0.02|

Frq = Mutation frequency.
mutations in Cluster 1 patients may involve changes in pathways including pancreatic cancer and TCA cycle (Figure 7d). In Cluster 2, patients with TP53 mutation and nonmutation had changes in multiple pathways, including phenylalanine metabolism, antigen processing and presentation, etc. (Figure 7e). For TP53 mutations in Cluster 4, there were some changed pathways between mutant and nonmutant patients, including base excision repair, homologous
recombination, cell cycle, etc. (Figure 7f). We only detected RGPD3 mutations in Cluster 3 patients. According to whether RGPD3 was mutated or not, the patients in Cluster 3 were divided into the mutation group and non-mutation group. It was found that there were differences between various pathways, including ubiquitin-mediated proteolysis, taurine and hypotaurine metabolism, MTOR signaling pathway, etc. (Figure 7g).

5 Discussion

In recent years, although there have been advances in treating PAAD, no joint research of drug metabolism-related genes with the immune infiltration and prognosis of PAAD has been performed. In this study, we screened prognostic differentially expressed genes related to drug metabolism of PAAD using data from public databases. We also constructed a PPI network and made an enrichment analysis for these genes screened above. Furthermore, unsupervised cluster analysis was used to divide these genes into four subgroups, and there were differences in survival, clinical, immune infiltration, and gene mutation among these subgroups.

In the PPI network constructed by 83 PAAD prognosis-related drug metabolism proteins, the relationship pair with the highest connection degree in the PPI network diagram was ABCC8-KCNJ11. However, the effect of their interaction on the prognosis of PAAD has not been reported before this study. ABCC8 was a member of the ATP-binding cassette (ABC) transporters family. It is well known that the higher expression levels of a large number of ABC transporter genes were associated with an increased chance of survival in patients with PAAD. However, ABCC8 was only confirmed to be an independent prognostic factor of glioma and has not been detected in any studied cell lines of PAAD [28]. Regarding KCNJ11, it is a member of the potassium channel gene family and interacted with ABCC8 to form ATP-sensitive potassium (KATP) channels mediating the secretion of insulin [29]. Besides, studies have shown that decreased co-expression of ABCC8-KCNJ11 may increase the risk of diabetes [30,31]. It is speculated that interacting proteins ABCC8-KCNJ11 may be involved in the prognosis of PAAD and can be used as a new prognostic factor for PAAD. In the PPI network, PPARG – RXRA showed the second-highest degree of connectivity. PPARG is a ligand-activated transcription factor that formed a heterodimer with RXRA. Research data show that both PPARG and RXRA were related to the characteristics of PAAD [32]. Moreover, it was found that PPARG (not RXRA) was an independent prognostic indicator.

After the unsupervised clustering analysis, four subgroups were obtained and Cluster 3 had a significantly better prognosis compared with the other three subgroups ($p < 0.05$). It was speculated that the good prognosis of Cluster 3 was not only because Cluster 3 had the most patients in the G1 stage and all of them showed a CR but also had a younger age. The abundance of immune infiltration between groups also showed differences. The abundance of M2 macrophages and activated NK cells in Cluster 3 were the highest and the abundance of M0 macrophages was the lowest in the four groups. It is well known that different phenotypes of macrophages have been demonstrated to play distinct roles in tumor progression [33]. M2 macrophages were divided into different subtypes by different stimuli, including M2a, M2b, M2c, and M2d. M2a activation is obtained by stimulating macrophages with IL-4 or IL-13 [34], M2b cells were elicited by stimulation with LPS or IL1beta. Unlike M2a cells, M2b cells produce large amounts of TNF-α, IL-1, and IL-6 in addition to IL-10. M2c cells were elicited by IL-10, GC, or TGF-β, and play an important role in the early stages of wound healing [35]. M2d cells were induced by A2AR signaling pursuant to initial stimulation by TLR agonists [36]. In this study, we compared the infiltration level of different M2 macrophages in the same subgroup and found that the infiltration level of M2b was the highest in the four subgroups. A previous study has found that an increase in the proportion of specific tumor-associated macrophages characterized by M2b can lead to acquired resistance to bevacizumab [37]. However, the role of the high infiltration level of M2b in PAAD patients needs further research in the future.

Furthermore, the mutation detection results of subgroups 1, 2, and 4 all showed a higher proportion of KRAS and TP53 mutations but these two mutations in cluster 3 did not appear in top10. The presence of KRAS mutation is generally associated with clinical aggressiveness of cancer and reduced survival of the patient [38]. A study has reported that KRAS and TP53 prognosis of PAAD is directly associated with a specific mutation of KRAS [39]. These results also further confirmed that the PAAD subgroup clustering and association analysis based on drug metabolism-related genes were effective. To further understand the role of gene mutations in different subtypes, we selected the genes with high missense mutation frequency (KRAS, TP53, RGPD3) in different subgroups. The results indicated that mutations in these genes may involve different pathway changes between different subgroups. Taurine
and hypotaurine metabolism, regulation of autophagy, phenylalanine metabolism, and other pathways have been confirmed to be involved in the occurrence of PAAD [40–42]. In addition, in this study, the two genes KRAS and TP53, which have a higher mutation frequency in a variety of cancers, did not appear in Cluster 3 patients, which is an interesting point. First of all, this classification of patient subgroups in this study was based on gene expression, and clinical characteristics were not included in the analysis. Therefore, the result is an unbiased analysis. Second, our cluster analysis included genes related to drug metabolism and genes that complete response to chemotherapy may be more similar in expression patterns, which leads to clustering such patients into a subgroup (Cluster 3). Patients in Cluster 3 will eventually have a better prognosis because of their good response to drugs.

The GSVA analysis of the differences between the four subgroups showed that the pathways with significant differences were mainly involved in the cell cycle, metabolism and synthesis of organic matter, response to stimulants such as drugs, and transmembrane transport. Mammalian cell cycle regulation is a very complicated process. The loss of function of key regulatory points can lead to uncontrolled cell proliferation and further tumors [43]. The difference in response to drug stimulation between different subgroups is consistent with our screening of drug metabolism-related goals, and in the analysis between subgroups, we also found that different groups had different responses to chemotherapy. The next research plan is to expand the number of samples and enrich the types of samples (including PAAD samples of different nationalities, etc.) for further confirming the role of data mining analysis and clustering analysis of drug metabolism-related genes on the prognosis and immune infiltration of PAAD disease. In addition, the highly connected drug metabolism-related gene relationship pairs in the PPI network need to be further verified in different PAAD subgroups.

6 Conclusion

In this study, through TCGA PAAD tumor data mining analysis, we constructed the PPI network composed of PAAD drug metabolism-related proteins and four different PAAD subgroups to investigate the possible molecular pathways related to the prognosis and immune infiltration of PAAD. The relationship pairs ABCG8 – KCNJ11 and PPARG – RXRA may be associated with the good performance on the PAAD prognosis. The genes involved in these relationship pairs may provide a basis for in-depth research on the prognosis mechanism of PAAD.

Acknowledgements: None.

Funding information: None.

Author contributions: Conception and design of the research: TZ; acquisition of data, analysis and interpretation of data: LZ and JC; statistical analysis: JH; drafting the manuscript: TZ; revision of the manuscript for important intellectual content: JH. All authors read and approved the final manuscript.

Conflict of interest: The authors declare that they have no conflicts of interest.

Data availability statement: All data generated or analyzed during this study are included in this published article.

References

[1] Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694.
[2] Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
[3] Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2(1):1–22.
[4] Karandish F, Mallik S. Biomarkers and targeted therapy in pancreatic cancer. Biomark Cancer. 2016;8:BIC. S34414.
[5] Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, et al. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut. 2020;69(8):1472–82.
[6] Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhal B, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–48.
[7] Ponz Sarwise M, Corbo V, Triaic H, Engle DD, Frese KK, Oni TE, et al. Identification of resistance pathways specific to malignancy using organoid models of pancreatic cancer. Clin Cancer Res. 2019;25(22):6742–55.
[8] Hwang RF, Gordon EM, Anderson WF, Parekh D. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery. 1998;124(2):143–51.
[9] Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 1992;256(5058):827–30.
[10] Ormanns S, Siveke JT, Heinemann V, Haas M, Sipos B, Schlitter AM, et al. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer. 2014;14(1):1–10.
[11] Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91(2):355–8.

[12] Marais R, Light Y, Paterson H, Marshall C. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 1995;14(13):3136–45.

[13] Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, et al. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. J Gastroenterol. 2013;48(4):544–8.

[14] Kim ST, Lim DH, Jang K-T, Lim T, Lee J, Choi Y-L, et al. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Therap. 2011;10(10):1993–9.

[15] Wang K, Zhan Y, Huynh N, Dumesny C, Wang X, Asadi K, et al. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumor immunity through down-regulation of PD-L1. Cancer Lett. 2020;472:8–18.

[16] Orhan A, Vogelsang RP, Andersen MB, Madsen MT, Hölmich ER, Raskov H, et al. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: A systematic review and meta-analysis. Eur J Cancer. 2020;132:71–84.

[17] Güreliev E, Fleischmann-Mundt B, Brooks J, Demir IE, Steiger K, Ribbach S, et al. Administration of gemcitabine after pancreatic tumor resection in mice induces an antitumor immune response mediated by natural killer cells. Gastroenterology. 2016;151(2):338–50.e7.

[18] Zweig AS, Karolchik D, Kuhn RM, Haussler D, Kent WJ. UCSC genome browser tutorial. Genomics. 2008;92(2):75–84.

[19] Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

[20] Pohar M, Stare J. Relative survival analysis in R. Computer Methods Prog Biomed. 2006;81(3):272–8.

[21] Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics: A J Integr Biol. 2012;16(5):284–7.

[22] Malika C, Ghazalli N, Boiteau V, Niknafs A. NbClust: an R package for determining the relevant number of clusters in a data set. J Stat Softw. 2014;61:1–36.

[23] Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–59.

[24] Kauppinnen IK, Moffatt DJ, Mantsch HH, Cameron DG. Fourier self-deconvolution: a method for resolving intrinsically overlapped bands. Appl Spectrosc. 1981;35(3):271–6.

[25] Huang X, Li Y, Fu M, Xin HB. Polarizing macrophages in vitro. Methods Mol Biol. (Clifton, NJ). 2018;1784:119–26.

[26] Loegl J, Hiden U, Nussbaumer E, Schliefsteiner C, Cvicic S, Lang I, et al. Hofbauer cells of M2a, M2b and M2c polarization may regulate feto-placental angiogenesis. Reprod (Cambridge, Engl). 2016;152:447–555.

[27] Mayakonda A, Lin D-C, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56.

[28] Hagmann W, Faisner R, Schnöller M, Löhr M, Jesnowski R. Membrane drug transporters and chemoresistance in human pancreatic carcinoma. Cancers. 2011;3(1):106–25.

[29] Haghvirdizadeh P, Mohamed Z, Abdullah NA, Haghvirdizadeh P, Haerian MS, Haerian BS. KCNJ11: genetic polymorphisms and risk of diabetes mellitus. J Diabetes Res. 2015;2015:908152.

[30] De Franco E, Saint-Martin C, Brusgaard K, Knight Johnson AE, Aguilar-Bryan L, Bowman P, et al. Update of variants identified in the pancreatic β-cell KATP channel genes KCNJ11 and ABCB3 in individuals with congenital hyperinsulinism and diabetes. Hum Mutat. 2020;41(5):884–905.

[31] Park SE, Flanagan SE, Hussain K, Ellard S, Shin CH, Yang SW. Characterization of ABCB8 and KCNJ11 gene mutations and phenotypes in Korean patients with congenital hyperinsulinism. Eur J Endocrinol. 2011;164(6):919–26.

[32] Giaginis C, Katsamangou E, Tsourouflis G, Zizi-Serbetzoglou D, Kouraklis G, Theocharis S. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients’ survival. Med Sci Monit. 2009;15(5):BR148–BR56.

[33] Wang Y, Lyu Z, Qin Y, Wang X, Sun L, Zhang Y, et al. FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma. Theranostics. 2020;10(25):11535–48.

[34] Zhang MZ, Wang X, Wang Y, Niu A, Wang S, Zou C, et al. IL-4/IL-13-mediated polarization of renal macrophages/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury. Kidney Int. 2017;91(2):375–86.

[35] Lurier EB, Dalton D, Dampier W, Raman P, Nassiri S, Ferraro NM, et al. Transcriptome analysis of IL-10-stimulated (M2c) macrophages by next-generation sequencing. Immunobiology. 2017;222(7):847–56.

[36] Grinberg S, Hasko G, Wu D, Leibovich SJ. Suppression of PLCbeta2 by endotoxin plays a role in the adenosine A2(A) receptor-mediated switch of macrophages from an inflammatory to an angiogenic phenotype. Am J Pathol. 2009;175(6):2439–53.

[37] Liu Y, Ji X, Kang N, Zhou J, Liang X, Li J, et al. Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced Bevacizumab resistance in triple-negative breast cancer. Cell Death Dis. 2020;11(11):1–13.

[38] Perincheri S, Hui P. KRAS mutation testing in clinical practice. Expert Rev Mol Diagnostics. 2015;15(3):375–84.

[39] Kaushik AC, Wang YJ, Wang X, Wei DQ. Ironocotan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations. Brief Bioinform. 2021;22(3):1–27.

[40] Wang S, Wen S, Guo P, Liu H, Feng J, Huang H. Understanding metabolomic characteristics of pancreatic ductal adenocarcinoma by HR-MAS NMR detection of pancreatic tissues. J Pharm Biomed Anal. 2020;190:113564.

[41] Boone BA, Zeh HJ III, Bahary N. Autophagy inhibition in pancreatic adenocarcinoma. Clin Colorectal Cancer. 2018;17(1):25–31.

[42] Helliwig D, Gouverneur E, Schaefer A, Raedle J, Menges M, Kirsch C-M, et al. Para-[123I] iodo-L-phenyalanine in patients with pancreatic adenocarcinoma. Nuklearmedizin. 2008;47(5):220–4.

[43] Kar S. Unraveling cell-cycle dynamics in cancer. Cell Syst. 2016;2(1):8–10.
Appendix

Figure A1: Flow chart.